Get started
Author

Chris Proffitt

Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth
2010 · Denis Drygin, Amy Lin, et al. · Cancer Research · 631
Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis
2009 · Denis Drygin, Adam Siddiqui-Jain, et al. · Cancer Research · 616
Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53
2012 · Megan J. Bywater, Gretchen Poortinga, et al. · Cancer Cell · 586
PDF
CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy
2010 · Adam Siddiqui-Jain, Denis Drygin, et al. · Cancer Research · 523
Discovery and SAR of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer
2010 · Fabrice Pierre, Peter C. Chua, et al. · Journal of Medicinal Chemistry · 306
Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics
2012 · Mustapha Haddach, Michael K. Schwaebe, et al. · ACS Medicinal Chemistry Letters · 170
Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer
2011 · Fabrice Pierre, Peter C. Chua, et al. · Molecular and Cellular Biochemistry · 155
CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy
2012 · Adam Siddiqui-Jain, Joshua Bliesath, et al. · Molecular Cancer Therapeutics · 110
Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor
2011 · Mustapha Haddach, Jerome Michaux, et al. · ACS Medicinal Chemistry Letters · 93
Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells
2012 · Joshua Bliesath, Nanni Huser, et al. · Cancer Letters · 76
Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer
2011 · Denis Drygin, Caroline B. Ho, et al. · Biochemical and Biophysical Research Communications · 73
Human NLRC4 expression promotes cancer survival and associates with type I interferon signaling and immune infiltration
2024 · Charlotte Domblides, Steven Crampton, et al. · Journal of Clinical Investigation · 18
PDF
Design and Discovery of a Potent and Selective Inhibitor of Integrin αvβ1
2024 · Mark Sabat, Daniel W. Carney, et al. · Journal of Medicinal Chemistry · 4
CX-4945, a Selective and Orally Bioavailable Inhibitor of Protein Kinase CK2 Inhibits PI3K/Akt, JAK-STAT and NF-κB Signaling and Induces Apoptosis In Multiple Myeloma Cells
2010 · Caroline Ho, Rachel Rice, et al. · Blood · 4
341 POSTER CX-5461, a novel, orally bioavailable selective small molecule inhibitor of RNA polymerase I transcription, induces autophagy and shows potent antitumor activity
2008 · D. Drygin, A. Lin, et al. · European Journal of Cancer Supplements · 2
Biochemical and Cellular Profile of NIK Inhibitors with Long Residence Times
2020 · Petro Halkowycz, Charles E. Grimshaw, et al. · SLAS DISCOVERY · 1
PDF
Abstract PR15: Inhibition of RNA Polymerase I as a therapeutic strategy for cancer-specific activation of p53
2011 · Megan J. Bywater, Kenna Anderes, et al. · Cancer Research · 1
Abstract 4511: CX-5461, a non-genotoxic activator of p53 through selective inhibition of RNA polymerase I for the treatment of hematological cancers
2011 · Denis Drygin, Caroline Ho, et al. · Cancer Research · 1
Abstract C198: CX-4945, a novel small molecule inhibitor of CK2 protein kinase, reduces hyperactivated Akt signaling and synergizes with Akt inhibitors in breast cancer cells
2009 · Denis Drygin, Josh Bliesath, et al. · Molecular Cancer Therapeutics · 1
Data from CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy
2023 · Adam Siddiqui-Jain, Joshua Bliesath, et al.
Data from CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy
2023 · Adam Siddiqui-Jain, Joshua Bliesath, et al.
Supplementary Methods, Figure Legends 1-3 from CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy
2023 · Adam Siddiqui-Jain, Joshua Bliesath, et al.
Supplementary Figure 2 from CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy
2023 · Adam Siddiqui-Jain, Joshua Bliesath, et al.
Supplementary Figure 3 from CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy
2023 · Adam Siddiqui-Jain, Joshua Bliesath, et al.
PDF
Supplementary Figure 1 from CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy
2023 · Adam Siddiqui-Jain, Joshua Bliesath, et al.
Works count: 38
Citation count: 3,371
H-index: 12
I10-index: 12
Year
Topic
Type